

**Home Health VNA**  
**IM/SC Medication Clinical Fact Sheet**

Medication: Canakinumab / Iliaris

Med Class: Anti-Rheumatic Monoclonal Antibodies, Interleukin-1 Beta Inhibitors

Common Uses: 

- Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Cold Auto-inflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS) in adults and children > 4 years of age
- Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
- Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Familial Mediterranean Fever (FMF) in adult and pediatric patients
- Active Still's disease, including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients > 2 years

---

Route(s): SC

Instructions / Precautions: 

- Instructions: Max dose adults based on disease, Max dose in children based on disease and weight. Injection solution should be essentially free of particulates, clear to opalescent, colorless to slightly brownish-yellow. Discard unused portion.
- DO NOT USE if brown discoloration, highly opalescent or contains highly visible particulates.
- Adverse effects: hypersensitivity, hepatitis, immunosuppression resulting in opportunistic infections, nasopharyngitis, upper respiratory tract infections, abdominal pain, injection site reactions, diarrhea, vertigo, MS pain, Macrophage Activation Syndrome (MAS) - life threatening disorder in patients with rheumatic disorders.
- Contraindications: - Hold if serious infection and contact MD, use of live vaccines while on Iliaris

---

First Dose Allowed:     N    

Special Training Required:     Y    

Additional References UpTo Date pdf should also be reviewed for required information prior to administration

Note: Nurse will not administer medication if special training is required and nurse has not received training; Contact your Clinical Manager immediately

Date Reviewed 11/16/2021